

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
15463ZYXWV (PC9003E)

Total Pages in this Submission

TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

RECOMBINANT FELINE CORONAVIRUS PROTEINS

22389 U.S. PTO
10/646874
118/22/03

and invented by:

Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter and Elaine V. Jones

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: 09/854,799

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: 08/392,459

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: 07/847,018

See Preliminary Amendment

Enclosed are:

Application Elements

1. Filing fee as calculated and transmitted as described below

2. Specification having 153 pages and including the following:
 - a. Descriptive Title of the Invention
 - b. Cross References to Related Applications (if applicable)
 - c. Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix
 - e. Background of the Invention
 - f. Brief Summary of the Invention
 - g. Brief Description of the Drawings (if filed)
 - h. Detailed Description
 - i. Claim(s) as Classified Below
 - j. Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
15463ZYXWV (PC9003E)

Total Pages in this Submission

Application Elements (Continued)

3. Drawing(s) (when necessary as prescribed by 35 USC 113)
a. Formal Number of Sheets 49 (Figs. 1-9H)
b. Informal Number of Sheets _____
4. Oath or Declaration
a. Newly executed (original or copy) Unexecuted
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
c. With Power of Attorney Without Power of Attorney
d. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. Application Data Sheet (See 37 CFR 1.76)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
a. Computer Readable Form (CRF)
b. Specification Sequence Listing on:
i. CD-ROM or CD-R (2 copies); or
ii. Paper
c. Statement(s) Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(B) Statement (when there is an assignee)
11. English Translation Document (if applicable)
12. Information Disclosure Statement/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. Certificate of Mailing
 First Class Express Mail (Specify Label No.): EV267607393 US

UTILITY PATENT APPLICATION TRANSMITTAL
(Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
15463ZYXWV (PC9003E)

Total Pages in this Submission

Acc mpanying Application Parts (Continued)

17. Additional Enclosures (please identify below):

Copy of Associate Power of Attorney Under 37 C.F.R. 1.34

Request to Use Computer Readable Form of Sequence Listing From Another Application.....

ASSIGNEE NAME: Pfizer, Inc.

ASSIGNEE RESIDENCE: New York, New York

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
15463ZYXWV (PC9003E)

Total Pages in this Submission

[] 9] Correspondence Address

Customer Number 23389

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee				
* Total Claims	41	- 20 =	21	x \$18.00	\$378.00				
* Indep. Claims	3	- 3 =	0	x \$84.00	\$0.00				
* Multipl Dependent Claims (check if applicable)	<input checked="" type="checkbox"/>				\$280.00				
					BASIC FEE \$750.00				
OTHER FEE (specify purpose)					\$0.00				
* Pls. calculate as amended by Preliminary Amendment					TOTAL FILING FEE \$1,408.00				

- A check in the amount of \$1,408.00 to cover the filing fee is enclosed.
 The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

- Charge the amount of _____ as filing fee.
- Credit any overpayment.
- Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).



Signature

Peter I. Bernstein
 Registration No. 43,497

Dated: August 22, 2003

cc: PIB/XZ:ab

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Docket No.

Applicant(s): Timothy J. Miller, et al.

15463ZYXWV (PC9003E)

Serial No.

To Be Assigned

Filing Date

Herewith

Examiner

Unassigned

Group Art Unit

Unassigned

Invention: RECOMBINANT FELINE CORONAVIRUS S PROTEINS

I hereby certify that the following correspondence:

New Utility Patent Application (Continuation)*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 22, 2003*(Date)*Peter I. Bernstein*(Typed or Printed Name)*
*(Signature of Person)*EV267607393 US*("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.